Wikipedia

BK-5-MAPBT

BK-5-MAPBT
Clinical data
Other namesbk-5-MAPBT; β-Keto-5-MAPBT
Drug classMonoamine releasing agent; Serotonin 5-HT1B receptor agonist; Entactogen
ATC code
  • None
Identifiers
  • 1-(1-benzothiophen-5-yl)-2-(methylamino)propan-1-one
CAS Number
PubChem CID
ChemSpider
Chemical and physical data
FormulaC12H13NOS
Molar mass219.30 g·mol−1
3D model (JSmol)
  • CC(C(=O)C1=CC2=C(C=C1)SC=C2)NC
  • InChI=1S/C12H13NOS/c1-8(13-2)12(14)10-3-4-11-9(7-10)5-6-15-11/h3-8,13H,1-2H3
  • Key:UUTCAMGZEOYTDB-UHFFFAOYSA-N

BK-5-MAPBT, also known as β-keto-5-MAPBT, is a possible entactogen of the benzothiophene and cathinone families.[1] It is a potent monoamine releasing agent, including of serotonin and dopamine, and also acts as a potent serotonin 5-HT1B receptor agonist.[1] Conversely, norepinephrine release was not reported.[1] Unlike non-cathinone benzothiophenes like 5-MAPBT and 6-MAPBT, BK-5-MAPBT is very weak or inactive as a serotonin 5-HT2B receptor antagonist and monoamine oxidase A (MAO-A) inhibitor.[1] It produces anxiolytic-like and antiobsessional-like effects in the marble burying test in rodents.[1] BK-5-MAPBT has been studied and patented by Matthew J. Baggott of Tactogen.[1]

See also

[edit]

References

[edit]
  1. ^ a b c d e f WO 2022010937A1, Baggott M, "Advantageous benzothiophene compositions for mental disorders or enhancement", published 13 January 2022, assigned to Tactogen Inc. 
Stub icon

This psychoactive drug-related article is a stub. You can help Wikipedia by expanding it.